Yu, Lio
Moloney, Mairead
Zheng, Songzhu
Rogers, James
Funding for this research was provided by:
SkinCure Oncology
Next Step Business Services, LLC
Article History
Received: 8 September 2022
Accepted: 24 January 2023
First Online: 28 January 2023
Declarations
:
: This study was performed in compliance with the pertinent sections of the Helsinki Declaration and its amendments. All methods were carried out in accordance with relevant guidelines and regulations. The protocol for this manuscript was reviewed by IRB (WCG IRB Affairs 1019 39th Ave SE, Suite 120, Puyallup, WA 98374) and was determined to be exempt from IRB approval under 45 CFR 46.104 (d)(4) with informed consent for the study waived because this retrospective chart review research involves the use of identifiable private information; and information is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify subjects. Any health information used in this study has been de-identified for use in this study.
: Not applicable.
: Dr. Lio Yu is the National Radiation Oncologist for Skin Cure Oncology and has received research, speaking and/or consulting support from Skin Cure Oncology. He has served on an advisory board for Bayer Pharmaceuticals previously. Mairead Moloney has no conflicts of interest to disclose. Songzhu Zheng has no conflicts of interest to disclose. Dr. James Rogers is a managing member of Summit Analytical, LLC, which was contracted to provide statistical analysis for this study. James Rogers received payment for the statistical analysis services he performed from, and thereby has a financial relationship with Next Step Business Services, LLC (a closely held company owned by Dr. Lio Yu). The payment to Dr. Rogers was made to his own closely held company known as Summit Analytical LLC).